Lupus therapeutic market is estimated to be valued at USD 3.25 Bn in 2024 and is expected to exhibit a CAGR of 8.9% over the forecast period (2024-2031). The lupus therapeutic market is witnessing steady growth with the increasing prevalence of lupus and growing government initiatives. Furthermore, increasing research and development activities focused on developing new and effective drugs for lupus treatment is fueling the market growth.
Market Dynamics:
The growth of the global lupus therapeutic market is driven by the increasing prevalence of lupus across the globe and growing government initiatives to spread awareness about the disease. As per recent data by the Lupus Foundation of America, around 1.5 million Americans and at least 5 million people worldwide suffer from a form of lupus. The rising incidence rate and lack of permanent cure for lupus has prompted pharmaceutical companies and governments to invest heavily in the development of new treatment therapies. Additionally, various government programs supporting lupus patients such as providing subsidized treatment and aid are further creating high demand for therapies in the market. While growing research provides opportunities for improved treatment options, high costs associated with lupus drugs remains a challenge.
Increasing Prevalence of Systemic Lupus Erythematosus (SLE) is Driving the Global Lupus Therapeutic Market
Systemic lupus erythematosus, commonly known as lupus, is an autoimmune disease that can damage any part of the body. According to the Lupus Foundation of America, around 1.5 million Americans and at least 5 million people worldwide have a form of lupus. The prevalence of lupus is the highest between the ages of 15 and 44, when the disease is nine times more common among women. The rising incidences of lupus cases globally is expected to fuel the demand for effective therapeutic drugs and treatment options for lupus patients. As there is no permanent cure available for lupus, patients rely lifelong on therapeutic medications to manage their disease symptoms and prevent complications. This growing patient pool diagnosed with lupus makes the market lucrative for lupus therapeutic drugs.
Growing Awareness and Diagnosis Rates are Boosting the Adoption of Lupus Therapeutics
Increasing awareness about lupus as a chronic illness with potentially serious complications if left untreated has encouraged more patients to seek medical help and get properly diagnosed. This is important as early and accurate diagnosis helps patients get the right treatment on time and monitor their condition closely. Also, with the availability of advanced diagnostic tests, it is now more possible to differentiate lupus from other similar conditions. Greater awareness combined with enhanced diagnostic capabilities has resulted in more lupus cases being identified and brought under the purview of physician care annually. This improves treatment seeking rate and positively impacts the sales volume of lupus therapeutics in the market.
High Cost of Biologics Hampers Their Widespread Consumption
The high cost of advanced biologic drugs used for treating severe and refractory cases of lupus poses a major restraint on the market. Biologics have revolutionized lupus management but come with an exceptionally high price tag, sometimes exceeding USD 100,000 per patient per year. They are not affordable for most patients, especially those relying on public or state health insurance programs with limited drug coverage or co-pay assistance. The steep cost of biologics restricts their accessibility, particularly in developing nations with lower per capita incomes. Unless more cost control and affordability measures are adopted, the high prices will continue discouraging optimal utilization of expensive yet effective biologics in the lupus therapeutic sector.
Side Effects of Long-term Corticosteroid Therapy Diminish Patient Compliance
Prolonged use of corticosteroid drugs prescribed for lupus can cause unwelcome side effects like weight gain, diabetes, osteoporosis, muscle weakness, etc. in the patients. This decreases tolerability and compliance to the treatment regimen over time. Non-adherence to drugs arises from bothersome medication side effects is a significant restraint in this market. Growing unwillingness to bear side effects hampers acceptance of corticosteroids which otherwise are mainstream therapeutic options for lupus. Unless safer and better tolerated alternatives are available, side effect risk will undermine consistent patient adherence critical for effective disease management.
Innovations in Drug Delivery Systems Create New Possibilities
Opportunities exist to further integrate addiction treatment into general medical care through collaborative models. Co-locating services within primary care, emergency departments, and hospital systems can improve identification and transitions to specialized support. Partnering addiction professionals with those addressing pain management, mental health issues, and chronic conditions holds promise. Alternative delivery settings outside traditional rehab also presents opportunities. Examples include workplaces, college campuses, prisons, supportive housing, and recovery community organizations. Greater integration and broader delivery settings can help overcome restraints while also reaching more individuals in need of care.
Combination Therapies Emerge as an Attractive Proposition
Combining drugs that work via different mechanisms provides a multi-targeted treatment approach with potential for superior outcomes over monotherapies. There is growing evidence that synergistic effects can be harnessed by blending conventional drugs with biologics or combining two biologics. Clinical trials evaluating combinations are underway based on their pharmacological rationale. If combination regimens prove more efficacious at managing active disease and preventing flares with lesser adverse effects, it could redefine treatment paradigms. This opportunity of developing fixed-dose combinations can give established players a competitive edge in the market.
Link: https://www.coherentmarketinsights.com/market-insight/lupus-therapeutic-market-4958
Key Development
- On March 14, 2024, Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, announced a collaboration with Artiva Biotherapeutics, Inc., a pharmaceutical company, on a Phase 1 trial of the company’s novel NK cell-based therapy, AlloNK (also known as AB-101), in combination with anti-CD20 antibodies, for patients with active lupus nephritis – inflammation of the kidneys caused by lupus.
- In September 2022, Otsuka Pharmaceutical Co., Ltd., a pharmaceutical company, announced that the European Commission (EC) had approved Lupkynis (voclosporin) in combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis (LN)
- In August 2021, AstraZeneca, a global pharmaceutical company, announced that the U.S. Food and Drug Administration approved Saphnelo (anifrolumab-fnia), a type I interferon (type I IFN) receptor antagonist, for treating moderate to severe systemic lupus erythematosus (SLE) in adult patients who are receiving standard therapy
- In December 2020, GSK plc., a pharmaceutical company, announced that the U.S. Food and Drug Administration had approved BENLYSTA (belimumab) for the treatment of adult patients with active lupus nephritis (LN) who are receiving standard therapy
Key Players: Hikma Pharmaceuticals PLC, Dr. Reddy's Laboratories Ltd., Amgen Inc., Novartis AG, Sanofi, UCB S.A., ImmuPharma PLC, Bayer AG, Merck & Co., Inc., Aurinia Pharmaceuticals Inc., Pfizer Inc., AstraZeneca, F.Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Boehringer Ingelheim International Gmbh
